Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TETON-OLE: Open-label Extension of Inhaled Treprostinil in Fibrotic Lung Disease
NCT04905693Phase 3Enrolling by invitation
- Sponsor
- United Therapeutics Corporation
- Start
- Sep 2022
- Primary completion
- Dec 2029
- Modality
- Orthosteric Ligands
- Countries
- 18
01
Overview
A Phase 3 trial of treprostinil in idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis (PF), sponsored by United Therapeutics Corporation. Started Sep 2022; status: enrolling by invitation.
02
Drugs
treprostinil
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT04905693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905693.